Biomimetic inhalable nanovesicles for enhanced cardiac therapy of heart failure following myocardial infarction.
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, and myocardial infarction (MI) frequently progresses to heart failure despite advances in contemporary therapies. A major barrier to the clinical translation of cardioprotective biologics is the lack of noninvasive, organ-targeted delivery...